Dr. Ruben Mesa, MD, director of the Mays Cancer Center, discusses the importance of developing racially inclusive clinical trials in myeloproliferative neoplasms (MPNs).
Newsroom
Dr. Ruben Mesa, MD, director of the Mays Cancer Center, discusses the importance of developing racially inclusive clinical trials in myeloproliferative neoplasms (MPNs).